+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Opium (Opioid) Addiction - Pipeline Review, H1 2020

  • ID: 5017416
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 161 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Adial Pharmaceuticals Inc
  • BioXcel Therapeutics Inc
  • Emergent BioSolutions Inc
  • Fab’entech SA
  • Nirsum Laboratories Inc
  • Pharmazz Inc
  • MORE
Opium (Opioid) Addiction - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2020, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 4, 14, 1, 25, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 5 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Adial Pharmaceuticals Inc
  • BioXcel Therapeutics Inc
  • Emergent BioSolutions Inc
  • Fab’entech SA
  • Nirsum Laboratories Inc
  • Pharmazz Inc
  • MORE
  • Introduction
  • Opium (Opioid) Addiction - Overview
  • Opium (Opioid) Addiction - Therapeutics Development
  • Opium (Opioid) Addiction - Therapeutics Assessment
  • Opium (Opioid) Addiction - Companies Involved in Therapeutics Development
  • Opium (Opioid) Addiction - Drug Profiles
  • Opium (Opioid) Addiction - Dormant Projects
  • Opium (Opioid) Addiction - Discontinued Products
  • Opium (Opioid) Addiction - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Opium (Opioid) Addiction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Adial Pharmaceuticals Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Alar Pharmaceuticals Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Amygdala Neurosciences Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Antheia Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Aphios Corp, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Aquilus Pharmaceuticals Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by Benuvia Therapeutics Inc, H1 2020
  • Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H1 2020
  • Opium (Opioid) Addiction - Dormant Projects, H1 2020
  • Opium (Opioid) Addiction - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Opium (Opioid) Addiction - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Opium (Opioid) Addiction, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Adial Pharmaceuticals Inc
  • Alar Pharmaceuticals Inc
  • Amygdala Neurosciences Inc
  • Antheia Inc
  • Aoxing Pharmaceutical Company Inc
  • Aphios Corp
  • Aquilus Pharmaceuticals Inc
  • Benuvia Therapeutics Inc
  • BioCorRx Inc
  • BioXcel Therapeutics Inc
  • Bridge Therapeutics Inc
  • Cessation Therapeutics LLC
  • Close Loop Medicine Ltd
  • Delpor Inc
  • DemeRx Inc
  • Elysium Therapeutics Inc
  • Emergent BioSolutions Inc
  • Ensysce Biosciences Inc
  • Eolas Therapeutics Inc
  • Epiodyne Inc
  • Ethismos Research Inc
  • Exxel Pharma Inc
  • Fab’entech SA
  • Indivior Plc
  • iX Biopharma Ltd
  • Lyndra Inc
  • Mayne Pharma Group Ltd
  • Mind Medicine Inc
  • Nirsum Laboratories Inc
  • Omeros Corp
  • Opiant Pharmaceuticals Inc
  • Orexigen Therapeutics Inc
  • Orexo AB
  • Orphomed Inc
  • Osmotica Pharmaceutical Corp
  • Pfizer Inc
  • Pharmazz Inc
  • Phoenix PharmaLabs Inc
  • Plumb Pharmaceuticals LLC
  • Serina Therapeutics Inc
  • Syntropharma Ltd
  • Titan Pharmaceuticals Inc
  • VDM Biochemicals Inc
  • Vivera Pharmaceuticals Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll